Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Licenses Use of Kinaxo Proteomics Platform

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies will make its KinaTor chemical proteomics technology available to Takeda San Diego researchers in drug discovery, preclinical research, and clinical development under an agreement announced this week.
 
Terms of the deal were not disclosed.
 
The KinaTor platform combines proprietary chemical proteomics technologies with mass spectrometry for the identification and characterization of a drug candidate’s native molecular targets in cell lines and tissue samples.
 
Takeda San Diego is a wholly owned subsidiary of Takeda Pharmaceutical, based in Osaka, Japan. Kinaxo is a privately held firm based in Martinsreid, Germany.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.